BACKGROUND: Hepatitis C virus (HCV) infection is both prevalent and undertreated. OBJECTIVE: To identify barriers to HCV treatment in primary care practice. DESIGN: Cross-sectional study. SETTING AND PARTICIPANTS: A cohort of 208 HCV-infected patients under the care of a primary care physician (PCP) between December 2001 and April 2004 at a single academically affiliated community health center. MEASUREMENTS: Data were collected from the electronic medical record (EMR), the hospital clinical data repository, and interviews with PCPs. MAIN RESULTS: Our cohort consisted of 208 viremic patients with HCV infection. The mean age was 47.6 (+/-9.7) years, 56% were male, and 79% were white. Fifty-seven patients (27.4% of the cohort) had undergone HCV treatment. Independent predictors of not being treated included: unmarried status (adjusted odds ratio [aOR] for treatment 0.36, P=.02), female gender (aOR 0.31, P=.01), current alcohol abuse (aOR 0.08, P=.0008), and a higher ratio of no-shows to total visits (aOR 0.005 per change of 1.0 in the ratio of no-shows to total visits, P=.002). The major PCP-identified reasons not to treat included: substance abuse (22.5%), patient preference (16%), psychiatric comorbidity (15%), and a delay in specialist input (12%). For 13% of the untreated patients, no reason was identified. CONCLUSIONS: HCV treatment was infrequent in our cohort of outpatients. Barriers to treatment included patient factors (patient preference, alcohol use, missed appointments), provider factors (reluctance to treat past substance abusers), and system factors (referral-associated delays). Multimodal interventions may be required to increase HCV treatment rates.
BACKGROUND:Hepatitis C virus (HCV) infection is both prevalent and undertreated. OBJECTIVE: To identify barriers to HCV treatment in primary care practice. DESIGN: Cross-sectional study. SETTING AND PARTICIPANTS: A cohort of 208 HCV-infectedpatients under the care of a primary care physician (PCP) between December 2001 and April 2004 at a single academically affiliated community health center. MEASUREMENTS: Data were collected from the electronic medical record (EMR), the hospital clinical data repository, and interviews with PCPs. MAIN RESULTS: Our cohort consisted of 208 viremic patients with HCV infection. The mean age was 47.6 (+/-9.7) years, 56% were male, and 79% were white. Fifty-seven patients (27.4% of the cohort) had undergone HCV treatment. Independent predictors of not being treated included: unmarried status (adjusted odds ratio [aOR] for treatment 0.36, P=.02), female gender (aOR 0.31, P=.01), current alcohol abuse (aOR 0.08, P=.0008), and a higher ratio of no-shows to total visits (aOR 0.005 per change of 1.0 in the ratio of no-shows to total visits, P=.002). The major PCP-identified reasons not to treat included: substance abuse (22.5%), patient preference (16%), psychiatric comorbidity (15%), and a delay in specialist input (12%). For 13% of the untreated patients, no reason was identified. CONCLUSIONS:HCV treatment was infrequent in our cohort of outpatients. Barriers to treatment included patient factors (patient preference, alcohol use, missed appointments), provider factors (reluctance to treat past substance abusers), and system factors (referral-associated delays). Multimodal interventions may be required to increase HCV treatment rates.
Authors: Cathey H Cawthorne; Kelly R Rudat; Mary S Burton; Kyle E Brown; Bruce A Luxon; Christine G Janney; Claus J Fimmel Journal: Am J Gastroenterol Date: 2002-01 Impact factor: 10.864
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough Journal: Ann Intern Med Date: 2002-02-19 Impact factor: 25.391
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais Journal: J Subst Abuse Treat Date: 2012-03-08
Authors: Yu-Hsiang Hsieh; Danielle Signer; Anuj V Patel; Valentina Viertel; Mustapha Saheed; Risha Irvin; Mark S Sulkowski; David L Thomas; Richard E Rothman Journal: Am J Emerg Med Date: 2018-08-29 Impact factor: 2.469
Authors: Yu-Hsiang Hsieh; Richard E Rothman; Oliver B Laeyendecker; Gabor D Kelen; Ama Avornu; Eshan U Patel; Jim Kim; Risha Irvin; David L Thomas; Thomas C Quinn Journal: Clin Infect Dis Date: 2016-02-21 Impact factor: 9.079
Authors: Daniel Radwan; Edward Cachay; Oluwaseun Falade-Nwulia; Richard D Moore; Ryan Westergaard; William Christopher Mathews; Judith Aberg; Laura Cheever; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore Journal: Can J Gastroenterol Date: 2013-04 Impact factor: 3.522